RNA respiratory viruses in solid organ transplantation

American Journal of Transplantation

Volumn 13, Issue SUPPL.4, 2013, Pages 212-219

  Manuel, O ^a   Estabrook, M ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Amantadine; influenza; oseltamivir; respiratory viral infections; vaccines

Indexed keywords

INFLUENZA VACCINE; OSELTAMIVIR; PALIVIZUMAB; PERAMIVIR; RIBAVIRIN; ZANAMIVIR;

ARTICLE; HUMAN; HUMAN METAPNEUMOVIRUS; INFLUENZA; INFLUENZA VIRUS; NONHUMAN; ORGAN TRANSPLANTATION; PARAINFLUENZA VIRUS; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY VIRUS; RHINOVIRUS; RHINOVIRUS INFECTION; RISK FACTOR;

ANTIVIRAL AGENTS; HUMANS; ORGAN TRANSPLANTATION; RESPIRATORY TRACT INFECTIONS; RISK FACTORS; RNA VIRUS INFECTIONS;

EID: 84874845112     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12113     Document Type: Article

References (76)

1. Ison MG,. Respiratory viral infections in transplant recipients. Antivir Ther 2007; 12: 627-638.
2. Couch RB, Englund JA, Whimbey E,. Respiratory viral infections in immunocompetent and immunocompromised persons. Am J Med 1997; 102 (3A): 2-9; discussion 25-6.
3. Lopez-Medrano F, Aguado JM, Lizasoain M, et al. Clinical implications of respiratory virus infections in solid organ transplant recipients: A prospective study. Transplantation 2007; 84: 851-856.
4. Peck AJ, Englund JA, Kuypers J, et al. Respiratory virus infection among hematopoietic cell transplant recipients: Evidence for asymptomatic parainfluenza virus infection. Blood 2007; 110: 1681-1688.
5. Billings JL, Hertz MI, Savik K, Wendt CH,. Respiratory viruses and chronic rejection in lung transplant recipients. J Heart Lung Transplant 2002; 21: 559-566.
6. Ison MG, Gubareva LV, Atmar RL, Treanor J, Hayden FG,. Recovery of drug-resistant influenza virus from immunocompromised patients: A case series. J Infect Dis 2006; 193: 760-764.
7. Khalifah AP, Hachem RR, Chakinala MM, et al. Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death. Am J Respir Crit Care Med 2004; 170: 181-187.
8. Kumar D, Erdman D, Keshavjee S, et al. Clinical impact of community-acquired respiratory viruses on bronchiolitis obliterans after lung transplant. Am J Transplant 2005; 5: 2031-2036.
9. Milstone AP, Brumble LM, Barnes J, et al. A single-season prospective study of respiratory viral infections in lung transplant recipients. Eur Respir J 2006; 28: 131-137.
10. Vu DL, Bridevaux PO, Aubert JD, Soccal PM, Kaiser L,. Respiratory viruses in lung transplant recipients: A critical review and pooled analysis of clinical studies. Am J Transplant 2011; 11: 1071-1078.
11. Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM,. Antiviral agents for the treatment and chemoprophylaxis of influenza-Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60: 1-24.
12. Englund JA, Piedra PA, Jewell A, Patel K, Baxter BB, Whimbey E,. Rapid diagnosis of respiratory syncytial virus infections in immunocompromised adults. J Clin Microbiol 1996; 34: 1649-1653.
13. Roghmann M, Ball K, Erdman D, Lovchik J, Anderson LJ, Edelman R,. Active surveillance for respiratory virus infections in adults who have undergone bone marrow and peripheral blood stem cell transplantation. Bone Marrow Transplant 2003; 32: 1085-1088.
14. Rovida F, Percivalle E, Zavattoni M, et al. Monoclonal antibodies versus reverse transcription-PCR for detection of respiratory viruses in a patient population with respiratory tract infections admitted to hospital. J Med Virol 2005; 75: 336-347.
15. Landry ML, Ferguson D,. SimulFluor respiratory screen for rapid detection of multiple respiratory viruses in clinical specimens by immunofluorescence staining. J Clin Microbiol 2000; 38: 708-711.
16. Mahony JB., Detection of respiratory viruses by molecular methods. Clin Microbiol Rev 2008; 21: 716-747.
17. Nolte FS, Marshall DJ, Rasberry C, et al. MultiCode-PLx system for multiplexed detection of seventeen respiratory viruses. J Clin Microbiol 2007; 45: 2779-2786.
18. Mahony J, Chong S, Merante F, et al. Development of a respiratory virus panel test for detection of twenty human respiratory viruses by use of multiplex PCR and a fluid microbead-based assay. J Clin Microbiol 2007; 45: 2965-2970.
19. Rand KH, Rampersaud H, Houck HJ,. Comparison of two multiplex methods for detection of respiratory viruses: FilmArray RP and xTAG RVP. J Clin Microbiol 2011; 49: 2449-2453.
20. Forman MS, Advani S, Newman C, Gaydos CA, Milstone AM, Valsamakis A,. Diagnostic performance of two highly multiplexed respiratory virus assays in a pediatric cohort. J Clin Virol 2012; 55: 168-172.
21. Hayden RT, Gu Z, Rodriguez A, et al. Comparison of two broadly multiplexed PCR systems for viral detection in clinical respiratory tract specimens from immunocompromised children. J Clin Virol 2012; 53: 308-313.
22. Pabbaraju K, Wong S, Tokaryk KL, Fonseca K, Drews SJ,. Comparison of the Luminex xTAG respiratory viral panel with xTAG respiratory viral panel fast for diagnosis of respiratory virus infections. J Clin Microbiol 2011; 49: 1738-1744.
23. Hammond SP, Gagne LS, Stock SR, et al. Respiratory virus detection with filmarray respiratory panel compared to conventional methods in immunocompromised patients. J Clin Microbiol 2012; 50: 3216-3221.
24. Caliendo AM,. Multiplex PCR and emerging technologies for the detection of respiratory pathogens. Clin Infect Dis 2011; 52 (Suppl 4): S326-S330.
25. Miller S, Moayeri M, Wright C, Castro L, Pandori M,. Comparison of GeneXpert FluA PCR to direct fluorescent antibody and respiratory viral panel PCR assays for detection of 2009 novel H1N1 influenza virus. J Clin Microbiol 2010; 48: 4684-4685.
26. Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S, et al. Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N Engl J Med 2009; 361: 680-689.
27. Kumar D, Michaels MG, Morris MI, et al. Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: A multicentre cohort study. Lancet Infect Dis 2010; 10: 521-526.
28. Cordero E, Perez-Romero P, Moreno A, et al. Pandemic influenza A (H1N1) virus infection in solid organ transplant recipients: Impact of viral and non-viral co-infection. Clin Microbiol Infect 2012; 18: 67-73.
29. Smud A, Nagel CB, Madsen E, et al. Pandemic influenza A/H1N1 virus infection in solid organ transplant recipients: A multicenter study. Transplantation 2010; 90: 1458-1462.
30. Low CY, Kee T, Chan KP, et al. Pandemic (H1N1) 2009 infection in adult solid organ transplant recipients in Singapore. Transplantation 2010; 90: 1016-1021.
31. Ng BJ, Glanville AR, Snell G, et al. The impact of pandemic influenza A H1N1 2009 on Australian lung transplant recipients. Am J Transplant 2011; 11: 568-574.
32. Minnema BJ, Patel M, Rotstein C, et al. Comparison of hospitalized solid organ transplant recipients and nonimmunocompromised patients with pandemic H1N1 infection: A retrospective cohort study. Transplantation 2011; 92: 230-234.
33. Kumar D, Blumberg EA, Danziger-Isakov L, et al. Influenza vaccination in the organ transplant recipient: Review and summary recommendations. Am J Transplant 2011; 11: 2020-2030.
34. Manuel O, Pascual M, Hoschler K, et al. Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients. Clin Infect Dis 2011; 52: 248-256.
35. Schuurmans MM, Tini GM, Dalar L, Fretz G, Benden C, Boehler A,. Pandemic 2009 H1N1 influenza virus vaccination in lung transplant recipients: Coverage, safety and clinical effectiveness in the Zurich cohort. J Heart Lung Transplant 2011; 30: 685-690.
36. Hurst FP, Lee JJ, Jindal RM, Agodoa LY, Abbott KC,. Outcomes associated with influenza vaccination in the first year after kidney transplantation. Clin J Am Soc Nephrol 2011; 6: 1192-1197.
37. Kumar D, Cordero E, Blumberg E, et al. A prospective multicenter study of seasonal influenza infection in transplant recipients. Abstract #308. American Transplant Congress. Boston, 2012.
38. Katerinis I, Hadaya K, Duquesnoy R, et al. De novo anti-HLA antibody after pandemic H1N1 and seasonal influenza immunization in kidney transplant recipients. Am J Transplant 2011; 11: 1727-1733.
39. Ison MG, Skakaly P, Shapira MY, Krivan G, Nist A, Dutkowski R,. Efficacy and safety of oral oseltamivir for influenza prophylaxis in transplant recipients. Antivir Ther 2012; 17: 955-964.
40. Ison MG, Sharma A, Shepard JA, Wain JC, Ginns LC,. Outcome of influenza infection managed with oseltamivir in lung transplant recipients. J Heart Lung Transplant 2008; 27: 282-288.
41. Khanna N, Steffen I, Studt JD, et al. Outcome of influenza infections in outpatients after allogeneic hematopoietic stem cell transplantation. Transplant Infect Dis 2009; 11: 100-105.
42. Watcharananan SP, Suwatanapongched T, Wacharawanichkul P, Chantratitaya W, Mavichak V, Mossad SB,. Influenza A/H1N1 2009 pneumonia in kidney transplant recipients: Characteristics and outcomes following high-dose oseltamivir exposure. Transplant Infect Dis 2010; 12: 127-131.
43. Lam H, Jeffery J, Sitar DS, Aoki FY,. Oseltamivir, an influenza neuraminidase inhibitor drug, does not affect the steady-state pharmacokinetic characteristics of cyclosporine, mycophenolate, or tacrolimus in adult renal transplant patients. Ther Drug Monit 2011; 33: 699-704.
44. Gaur AH, Bagga B, Barman S, et al. Intravenous zanamivir for oseltamivir-resistant 2009 H1N1 influenza. N Engl J Med 2010; 362: 88-89.
45. Hernandez JE, Adiga R, Armstrong R, et al. Clinical experience in adults and children treated with intravenous peramivir for 2009 influenza A (H1N1) under an Emergency IND program in the United States. Clin Infect Dis 2011; 52: 695-706.
46. Ison MG. Antivirals and resistance: Influenza virus. Curr Opin Virol 2011; 1: 563-573.
47. Calatayud L, Lackenby A, Reynolds A, et al. Oseltamivir-resistant pandemic (H1N1) 2009 virus infection in England and Scotland, 2009-2010. Emerg Infect Diseases 2011; 17: 1807-1815.
48. Bellau-Pujol S, Vabret A, Legrand L, et al. Development of three multiplex RT-PCR assays for the detection of 12 respiratory RNA viruses. J Virol Methods 2005; 126: 53-63.
49. Flynn JD, Akers WS, Jones M, et al. Treatment of respiratory syncytial virus pneumonia in a lung transplant recipient: Case report and review of the literature. Pharmacotherapy 2004; 24: 932-938.
50. Krinzman S, Basgoz N, Kradin R, et al. Respiratory syncytial virus-associated infections in adult recipients of solid organ transplants. J Heart Lung Transplant 1998; 17: 202-210.
51. McCurdy LH, Milstone A, Dummer S,. Clinical features and outcomes of paramyxoviral infection in lung transplant recipients treated with ribavirin. J Heart Lung Transplant 2003; 22: 745-753.
52. Wendt CH,. Community respiratory viruses: Organ transplant recipients. Am J Med 1997; 102: 31-36; discussion 42-3.
53. Blanchard SS, Gerrek M, Siegel C, Czinn SJ,. Significant morbidity associated with RSV infection in immunosuppressed children following liver transplantation: Case report and discussion regarding need of routine prophylaxis. Pediatr Transplant 2006; 10: 826-829.
54. Raad I, Abbas J, Whimbey E,. Infection control of nosocomial respiratory viral disease in the immunocompromised host. Am J Med 1997; 102: 48-52; discussion 3-4.
55. Siegel JD, Rhinehart E, Jackson J, Chiarello L,. Committee atHICPA. 2007 Guideline for Isolation Precautions: Preventing Transmission of Ifnectious Agents in Healthcare Settings. Vol. http://www.cdc.gov/ncidod/dhqp/pdf/ isolation2007.pdf, 2007.
56. Groothuis JR, Simoes EA, Levin MJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group. N Engl J Med 1993; 329: 1524-1530.
57. Thomas NJ, Hollenbeak CS, Ceneviva GD, Geskey JM, Young MJ,. Palivizumab prophylaxis to prevent respiratory syncytial virus mortality after pediatric bone marrow transplantation: A decision analysis model. J Pediatr Hematol Oncol 2007; 29: 227-232.
58. Pickering L, Baker C, Kimberlin D, Long S, eds. Respiratory syncitial virus. 28th Ed. Elk Grove Village, IL: American Academy of Pediatrics, 2009.
59. Michaels MG, Fonseca-Aten M, Green M, et al. Respiratory syncytial virus prophylaxis: A survey of pediatric solid organ transplant centers. Pediatr Transplant 2009; 13: 451-456.
60. Danziger-Isakov LA, Arslan D, Sweet S, Benden C, Goldfarb S, Wong J,. RSV prevention and treatment in pediatric lung transplant patients: A survey of current practices among the International Pediatric Lung Transplant Collaborative. Pediatr Transplant 2012; 16: 638-644.
61. Boeckh M, Englund J, Li Y, et al. Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infections in hematopoietic cell transplant recipients. Clin Infect Dis 2007; 44: 245-249.
62. Ariza-Heredia EJ, Fishman JE, Cleary T, Smith L, Razonable RR, Abbo L,. Clinical and radiological features of respiratory syncytial virus in solid organ transplant recipients: A single-center experience. Transpl Infect Dis 2012; 14: 64-71.
63. Nichols WG, Gooley T, Boeckh M,. Community-acquired respiratory syncytial virus and parainfluenza virus infections after hematopoietic stem cell transplantation: The Fred Hutchinson Cancer Research Center experience. Biol Blood Marrow Transplant 2001; 7 (Suppl): 11S-5S.
64. Chavez-Bueno S, Mejias A, Merryman RA, Ahmad N, Jafri HS, Ramilo O,. Intravenous palivizumab and ribavirin combination for respiratory syncytial virus disease in high-risk pediatric patients. Pediatr Infect Dis J 2007; 26: 1089-1093.
65. Liu V, Dhillon GS, Weill D,. A multi-drug regimen for respiratory syncytial virus and parainfluenza virus infections in adult lung and heart-lung transplant recipients. Transpl Infect Dis 2010; 12: 38-44.
66. Pelaez A, Lyon GM, Force SD, et al. Efficacy of oral ribavirin in lung transplant patients with respiratory syncytial virus lower respiratory tract infection. J Heart Lung Transplant 2009; 28: 67-71.
67. Glanville AR, Scott AI, Morton JM, et al. Intravenous ribavirin is a safe and cost-effective treatment for respiratory syncytial virus infection after lung transplantation. J Heart Lung Transplant 2005; 24: 2114-2119.
68. Li L, Avery R, Budev M, Mossad S, Danziger-Isakov L,. Oral versus inhaled ribavirin therapy for respiratory syncytial virus infection after lung transplantation. J Heart Lung Transplant 2012; 31: 839-844.
69. Vilchez RA, Dauber J, McCurry K, Iacono A, Kusne S,. Parainfluenza virus infection in adult lung transplant recipients: An emergent clinical syndrome with implications on allograft function. Am J Transplant 2003; 3: 116-120.
70. Hopkins P, McNeil K, Kermeen F, et al. Human metapneumovirus in lung transplant recipients and comparison to respiratory syncytial virus. Am J Respir Crit Care Med 2008; 178: 876-881.
71. Raza K, Ismailjee SB, Crespo M, et al. Successful outcome of human metapneumovirus (hMPV) pneumonia in a lung transplant recipient treated with intravenous ribavirin. J Heart Lung Transplant 2007; 26: 862-864.
72. Safdar A,. Immune modulatory activity of ribavirin for serious human metapneumovirus disease: Early i.v. therapy may improve outcomes in immunosuppressed SCT recipients. Bone Marrow Transplant 2008; 41: 707-708.
73. Ison MG, Hayden FG, Kaiser L, Corey L, Boeckh M,. Rhinovirus infections in hematopoietic stem cell transplant recipients with pneumonia. Clin Infect Dis 2003; 36: 1139-1143.
74. Kaiser L, Aubert JD, Pache JC, et al. Chronic rhinoviral infection in lung transplant recipients. Am J Respir Crit Care Med 2006; 174: 1392-1399.
75. van Kraaij MG, van Elden LJ, van Loon AM, et al. Frequent detection of respiratory viruses in adult recipients of stem cell transplants with the use of real-time polymerase chain reaction, compared with viral culture. Clin Infect Dis 2005; 40: 662-669.
76. DeVincenzo J, Lambkin-Williams R, Wilkinson T, et al. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci USA 2010; 107: 8800-8805.